News Feeds

HealthFolk's News section is a health news aggregator with a focus on Nigeria, and Africa as a whole.

[Department of Error] Department of Error

Tags: General

Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394: 1915–28—In figure 2 of this Article, the data curves in panel G were mistakenly copied from panel F. The milestone percentages, numbers at risk, and the interpretation of the figure remain unchanged. In table 1, the number of female participants in the cetuximab with chemotherapy group was corrected from “93 (17%)” to “36 (13%)”. In the second paragraph of the Results, the number of participants in the cetuximab with chemotherapy group who received a subsequent PD-1 or PD-L1 inhibitor was corrected from “74 (25%)” to “75 (25%)”. The appendix has also been updated to reflect this change. These corrections have been made to the online version as of Feb 20, 2020.

Linked Articles

Read more at the original link...


Read On:

Are you a doctor? Click here and signup to join medical discussion forums, and receive medical job alerts! Free!

Medical Jobs



Most Recent

Doctor? Click here to signup to receive news & research in your specialty